

## MODIFIED HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR AND PROCESS FOR PRODUCING SAME

### Cross Reference to Related Application

5 This application is a continuation patent application of PCT Patent Application No. PCT/KR00/00733, which was filed on July 7, 2000, designating the United States of America, now abandoned.

### Field of the Invention

10 The present invention relates to a modified human granulocyte-colony stimulating factor(hG-CSF), a gene encoding said peptide, a vector comprising said gene, a microorganism transformed with said vector and a process for producing the modified hG-CSF using said microorganism.

### Background of the Invention

15 The term colony stimulating factor (CSF) is inclusive of granulocyte/macrophage-colony stimulating factor(GM-CSF), macrophage-colony stimulating factor(M-CSF) and granulocyte-colony stimulating factor(G-CSF), which are produced by T-cells, macrophages, fibroblasts and endothelial  
20 cells. GM-CSF stimulates stem cells of granulocyte or macrophage to induce the differentiation thereof and proliferation of granulocyte or macrophage colonies. M-CSF and G-CSF primarily induce the formation of the colonies of macrophage and granulocyte, respectively. In vivo, G-CSF induces the differentiation of bone marrow leucocytes and enhances the function of mature  
25 granulocyte and, accordingly, it's clinical importance in treating leukemia has been well established.

Human G-CSF(hG-CSF) is a protein consisting of 174 or 177 amino acids, the 174 amino-acid variety having higher neutrophil-enhancing activity(Morishita, K. et al., J. Biol. Chem., 262, 15208-15213(1987)). The  
30 amino acid sequence of hG-CSF consisting of 174 amino acids is shown in Fig. 1 and there have been many studies for the mass production of hG-CSF by manipulating a gene encoding said hG-CSF.

For instance, Chugai Pharmaceuticals Co., Ltd.(Japan) has disclosed the amino acid sequence of hG-CSF and a gene encoding same(Korean Patent  
35 Publication Nos. 91-5624 and 92-2312), and reported a method for preparing proteins having hG-CSF activity by a gene recombination process(Korean

Patent Nos. 47178, 53723 and 57582). In this preparation method, glycosylated hG-CSF is produced in a mammalian cell by employing a genomic DNA or cDNA comprising a polynucleotide encoding hG-CSF. The glycosylated hG-CSF has an O-glycosidic sugar chain, but, it is known that said sugar chain is not necessary for the activity of hG-CSF(Lawrence, M. et al., Science, 232, 61(1986)). Further, it is also well-known that the production of glycosylated hG-CSF employing mammalian cells requires expensive materials and facilities, and therefore, such a process is not economically feasible.

Meanwhile, there have been attempts to produce non-glycosylated hG-CSF by employing a microorganism, e.g., *E. coli*. In these studies, hG-CSFs having 175 or 178 amino acids having a methionine residue attached at the N-terminus thereof are obtained due to the ATG initiation codon employed in the microorganism. The additional methionine residue, however, causes undesirable immune responses in human body when the recombinant hG-CSF is administered thereto(European Patent Publication No. 256,843). Further, most of the methionine-containing hG-CSFs produced in *E. coli* are deposited in the cells as insoluble inclusion bodies, and they must be converted to an active form through a refolding process, at a significant loss of yield. In this regard, four of the five Cys residues present in wild-type hG-CSF participate in forming disulfide bonds, while the remaining one contributes to the aggregation of the hG-CSF product during the refolding process to lower the yield.

Recently, in order to solve the problems associated with the production of a foreign protein within a microbial cell, various efforts have been made to develop a method based on efficient secretion of a target protein across the microbial cell membrane into the extra-cellular domain.

For instance, in a method employing a signal peptide, a desired protein is expressed in the form of a fusion protein wherein a signal peptide is added to the N-terminus of the protein. When the fusion protein passes through the cell membrane, the signal peptide is removed by an enzyme and the desired protein is secreted in a mature form. The secretory production method is advantageous in that the produced amino acid sequence is usually identical to the wild-type. However, the yield of a secretory production method is often quite low due to unsatisfactory efficiencies in both the membrane transport and the subsequent purification process. This is in line with the well-known fact that the yield of a mammalian protein produced in a secretory mode in prokaryotes is very low: Hitherto, no microbial method has been reported for

the efficient expression and secretion of soluble hG-CSF having no added methionine residue at its N-terminus.

The present inventors have previously reported the use of a new secretory signal peptide prepared by modifying the signal peptide of E. coli thermoresistant enterotoxin II(Korean Patent Laid-open publication No. 2000-19788) in the production of hG-CSF. Specifically, an expression vector comprising a hG-CSF gene attached to the 3'-end of the modified signal peptide of E. coli thermoresistant enterotoxin II was prepared, and biologically active, mature hG-CSF was expressed by employing E. coli transformed with the expression vector. However, most of the expressed hG-CSF accumulated in the cytoplasm rather than in the periplasm.

The present inventors have endeavored further to develop an efficient secretory method for the production of hG-CSF in a microorganism and have found that a modified hG-CSF, which is prepared by replacing at least one amino acid residue, especially, the 17th cysteine residue, of wild-type hG-CSF with other amino acid, retains the biological activity of the wild-type, and that the modified hG-CSF having no methionine residue at the N-terminus thereof can be efficiently expressed and secreted by a microorganism when an appropriate secretory signal peptide is employed.

### **Summary of the Invention**

Accordingly, it is an object of the present invention to provide a modified human granulocyte-stimulating factor(hG-CSF) which can be efficiently produced using a microorganism..

It is another object of the present invention to provide a gene encoding said peptide and a vector comprising said gene.

It is a further object of the present invention to provide a microorganism transformed with said vector.

It is a still further object of the present invention to provide a process for producing a hG-CSF which is non-attached methionine residue to amino terminus using said microorganism.

In accordance with one aspect of the present invention, there is provided a modified hG-CSF characterized in that at least one of the 1st, 2nd, 3rd and 17th amino acids of wild-type hG-CSF is replaced by another amino acid.

## **Brief Description of the Drawings**

The above and other objects and features of the present invention will become apparent from the following description of the invention taken in conjunction with the following accompanying drawings; which respectively show:

- Fig.1 : the nucleotide and amino acid sequences of wild-type human granulocyte-stimulating factor composed of 174 amino acids residues(SEQ ID NOS: 1 and 2);
- Fig. 2 : the procedure for constructing vector pT-CSF;
- Fig. 3 : the procedure for constructing vector pT14S1SG;
- Fig. 4 : the procedure for constructing vector pT14SS1SG;
- Fig. 5 : the procedure for constructing vector pT140SSG-4T22Q;
- Fig. 6 : the procedure for constructing vector pT14SS1S17SEG;
- Fig. 7 : the procedure for constructing vector pTO1SG;
- Fig. 8 : the procedure for constructing vector pBADG;
- Fig. 9 : the procedure for constructing vector pBAD2M3VG;
- Figs. 10a and 10b : the results of western blot analyses which verify the expression of hG-CSF and modified hG-CSFs from recombinant cell lines and the molecular weight of expressed proteins, respectively; and
- Fig. 11 : the cellular activities of hG-CSF and modified hG-CSF produced from recombinant cell lines.

## **Detailed Description of the Invention**

- The modified hG-CSFs of present invention are derived by replacing one or more of the amino acids of wild-type hG-CSF(SEQ ID NO: 2), preferably the 1st, 2nd, 3rd and 17th amino acids thereof, by other amino acids. More preferred are those obtained by replacing the 17th amino acid of hG-CSF with an amino acid which is uncharged at neutral pH. Specific examples of preferred modified hG-CSFs have the amino acid sequence of wild-type hG-CSF, except that:
- (a) the 1st amino acid is Ser;
  - (b) the 1st amino acid is Ser and the 17th amino acid is X;
  - (c) the 2nd amino acid is Met and the 3rd amino acid is Val;

(d) the 2nd amino acid is Met, the 3rd amino acid is Val and the 17th amino acid is X; or

(f) the 17th amino acid is X,

wherein X is an amino acid which is not charged at neutral pH.,  
5 preferably Ser, Thr, Ala or Gly, more preferably Ser.

Four of the five Cys residues of hG-CSF participate in forming disulfide bonds, while the 17th Cys residue remains unbonded in the natural state. However, when a large amount of hG-CSF is expressed in recombinant  
10 cells, the 17th Cys residue gets involved in inter-molecular disulfide bond formation, leading to the accumulation of agglomerated hG-CSFs in the cytoplasm. However, the inventive modified hG-CSF having an amino acid other than Cys at the 17th position is free of such problem and can be effectively produced by a secretory method using an appropriately transformed  
15 microorganism.

The modified hG-CSF of the present invention may be encoded by a gene comprising a nucleotide sequence deduced from the modified hG-CSF amino acid sequence according to the genetic code. It is known that several different codons encoding a specific amino acid may exist due to the codon  
20 degeneracy, and, therefore, the present invention includes in its scope all nucleotide sequences deduced from the modified hG-CSF amino acid sequence. Preferably, the modified hG-CSF gene sequence includes one or more preferred codons of *E. coli*.

The gene thus prepared may be inserted to a conventional vector to  
25 obtain an expression vector, which may, in turn, be introduced into a suitable host, e.g., an *E. coli*. The expression vector may further comprise a signal peptide. Representative signal peptides include a thermoresistant *E. coli* enterotoxin II signal peptide(SEQ ID NO: 53), a modified thermoresistant *E. coli* enterotoxin II signal peptide(SEQ ID NO: 54), a beta lactamase signal  
30 peptide(SEQ ID NO: 24), Gene III signal peptide(SEQ ID NO: 42) or modified peptide thereof, but these do not limit the signal peptides which may be used in the present invention. The promoter used in preparing the expression vector of present invention may be any of those which can express a heterologous protein in a microorganism host. Specially, lac, Tac, and arabinose promoter is  
35 preferred when the heterologous protein is expressed from *E. coli*.

Exemplary expression vector of the present invention includes

pT14SS1SG, pT14SS1S17SEG, pTO1SG, pTO1S17SG, pTO17SG, pTO17TG, pTO17AG, pTO17GG, pBAD2M3VG, pBAD17SG and pBAD2M3V17SG.

The expression vectors of the present invention may be introduced into microorganism, e.g., *E. coli* BL21(DE3)(Novagen), *E. coli* XL-1 blue(Novagen) according to a conventional transformation method(Sambrook et al., the supra) to obtain transformants *E. coli* BL21(DE3)/pT14SS1SG(HM 10310), *E. coli* BL21(DE3)/pT14SS1S17SEG(HM 10311), *E. coli* BL21(DE3)/pTO1SG(HM 10409), *E. coli* BL21(DE3)/pTO1S17SG(HM 10410), *E. coli* BL21(DE3)/pTO17SG(HM 10411), *E. coli* BL21(DE3)/pTO17TG(HM 10413), *E. coli* BL21(DE3)/pTO17AG(HM 10414), *E. coli* BL21(DE3)/pTO17GG(HM 10415), *E. coli* BL21(DE3)/pBAD2M3VG(HM 10510), *E. coli* BL21(DE3)/pBAD17SG(HM 10511) and *E. coli* BL21(DE3)/pBAD2M3V17SG(HM 10512). Among the transformed microorganism, preferred are transformants *E. coli* BL21(DE3)/pT14SS1S17SEG(HM 10311), *E. coli* BL21(DE3)/pTO1S17SG(HM 10410), *E. coli* BL21(DE3)/pTO17SG(HM 10411) and *E. coli* BL21(DE3)/pBAD2M3VG(HM 10510) which were deposited with Korean Culture Center of Microorganisms(KCCM)(Address; Department of Food Engineering, College of Eng., Yonsei University, Sodaemun-gu, Seoul 120-749, Republic of Korea) on March 24, 1999 under accession numbers KCCM-10154, KCCM-10151, KCCM-10152 and KCCM-10153, respectively, in accordance with the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganism for the Purpose of Patent Procedure.

The modified hG-CSF protein of the present invention may be produced by culturing the transformant microorganism to express the gene encoding the modified hG-CSF protein and secrete the modified hG-CSF, protein to periplasm; and recovering the modified hG-CSF protein from the periplasm. The transformant microorganism may be cultured in accordance with a conventional method(Sambrook et al., the supra). The microorganism culture may be centrifuged or filtered to collect the microorganism secreting the modified hG-CSF protein. The transformed microorganism may be disrupted according to a conventional method(Ausubel, F. M. et al., Current Protocols in Molecular Biology, (1989)) to obtain a periplasmic solution. For example, the microorganism may be disrupted in a hypotonic solution, e.g., distilled water, by an osmotic shock. Recovery of the modified hG-CSF in the periplasmic

solution may be conducted by a conventional method(Sambrook et al., the supra), e.g., ion exchange chromatography, gel filtration column chromatography or immune column chromatography. For example, hG-CSF may be purified by sequentially conducting CM-Sepharose column chromatograph and Phenyl Sepharose column chromatography.

The modified hG-CSF protein produced according to the present invention is not methionylated at the N-terminus and has biological activity which is equal to, or higher than, that of wild-type hG-CSF. Therefore, it may be used as is in various applications

The following Examples are intended to further illustrate the present invention without limiting its scope.

#### Example 1: Preparation of A Gene Encoding hG-CSF

A cDNA gene encoding hG-CSF was prepared by carrying out PCR using as an hG-CSF template(R&D system, USA). The primers used are those described in US patent No. 4,810,643.

To prepare a cDNA gene encoding mature hG-CSF, vector pUC19-G-CSF(Biolabs, USA) was subjected to PCR using the primers of SEQ ID NOS: 3 and 4. The primer of SEQ ID NO: 3 was designed to provide an NdeI restriction site(5'-CATATG-3') upstream from the first amino acid(threonine) codon of mature hG-CSF, and the primer of SEQ ID NO: 4, to provide a BamHI restriction site(5'-GGATCC-3') downstream from the termination codon thereof.

The amplified hG-CSF gene was cleaved with NdeI and BamHI to obtain a gene encoding mature hG-CSF. The hG-CSF gene was inserted at the NdeI/BamHI section of vector pET14b(Novagen, USA) to obtain vector pT-CSF.

Fig. 2 shows the above procedure for constructing vector pT-CSF.

#### Example 2: Construction of a vector containing the gene encoding *E. coli* enterotoxin II signal peptide and a modified hG-CSF

(Step 1) Cloning *E. coli* enterotoxin II signal peptide gene

To prepare *E. coli* enterotoxin II signal peptide gene, the pair of complementary oligonucleotides having SEQ ID NOS: 5 and 6 were designed

based on the nucleotide sequence of *E. coli* enterotoxin II signal peptide, and synthesized using DNA synthesizer(Model 380B, Applied Biosystem, USA).

The above oligonucleotides were designed to provide BspHI restriction site(complementary sites to an NcoI restriction sites) upstream from the initiation codon of *E. coli* enterotoxin II and an MluI restriction site introduced by a silent change at the other end.

Both oligonucleotides were annealed at 95 °C to obtain blunt-ended DNA fragments having a nucleotide sequence encoding *E. coli* enterotoxin II signal peptide(STII gene).

The STII gene was inserted at the SmaI site of vector pUC19(Biolabs, USA) to obtain vector pUC19ST.

#### (Step 2) Preparation of a gene encoding STII/hG-CSF

To prepare a gene encoding STII/hG-CSF, vector pT-CSF obtained in Preparation Example 1 was subjected to PCR using the primers of SEQ ID NOS: 7 and 8. The primer of SEQ ID NO: 7 was designed to substitute Ser codon for the first codon of hG-CSF, and the primer of SEQ ID NO: 8, to provide a BamHI restriction site(5'-GGATCC-3') downstream from the termination codon thereof.

The amplified DNA fragments were cleaved with MluI and BamHI, and then inserted at the MluI/BamHI section of pUC19ST obtained in Step 1 to obtain vector pUC19S1SG. Vector pUC19S1SG thus obtained contained a gene encoding an STII/hG-CSF(designated STII-hG-CSF gene).

Vector pUC19S1SG was cleaved with BspHI and BamHI to obtain a DNA fragment(522 bp). The DNA fragment was inserted at the NcoI/BamHI section of vector pET14b(Novagen, USA) to obtain vector pT14S1SG.

Fig. 3 depicts the above procedure for constructing vector pT14S1SG.

#### (Step 3) Addition of *E. coli* enterotoxin II Shine-Dalgarno sequence to STII-hG-CSF gene

Vector pT14S1SG obtained in Step 2 was subjected to PCR using the primers of SEQ ID NOS: 9 and 10. The primer of SEQ ID NO: 9 was designed to provide an *E. coli* enterotoxin II Shine-Dalgarno sequence(designated STII SD sequence) and an XbaI restriction site, and the



primer of SEQ ID NO: 10, to provide a BamHI restriction site downstream from the termination codon of mature hG-CSF to obtain a DNA fragment(STII SD-STII-hCSF) containing a STII SD and STII-hG-CSF gene.

5 The STII SD-STII-hG-CSF fragment was cleaved with XbaI and BamHI, and then inserted at the XbaI/BamHI section of vector pET14b(Novagen, USA) to obtain vector pT14SS1SG.

Fig. 4 displays the above procedure for constructing vector pT14SS1SG.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pT14SS1SG to obtain a transformant designated *E. coli* HM 10310.

10

(Step 4) Construction of a vector containing a gene encoding STII/hG-CSF fusion protein

15 The first codon of the modified hG-CSF gene of plasmid pT14SS1SSG obtained in Step 3 was replaced by Thr in accordance with a site-directed mutagenesis(Papworth, C. et al., Strategies, 9, 3(1996)), which was conducted by PCR of the plasmid with a sense primer(SEQ ID NO: 12) having a modified nucleotide sequence, a complementary antisense primer(SEQ ID NO: 13), and pfu(Stragene, USA).

20 The amplified DNA fragment was recovered and restriction enzyme DpnI was added thereto to remove unconverted plasmids.

*E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pT14SSG which contained a  
25 gene having Thr in place of the first amino acid of hG-CSF(SEQ ID NO: 11).

	-5	-4	-3	-2	-1	+1	+2	+3	+4	+5	
	Thr	Asn	Ala	Tyr	Ala	Thr	Pro	Leu	Gly	Pro	(SEQ ID NO: 11)
	-	ACA	AAT	GCC	TAC	GCG	ACA	CCC	CTG	GGC	CCT (SEQ ID NO: 12)
30	-	TGT	TTA	CGG	ATG	CGC	TGT	GGG	GAC	CCG	GGA (SEQ ID NO: 13)

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pT14SSG to obtain a transformant designated *E. coli* HM 10301.

35

(Step 5) Construction of a vector containing a gene encoding modified STII /hG-CSF

5 Vector pT14SSG obtained in Step 4 was subjected to PCR using the complementary primers of SEQ ID NOS: 15 and 16, which were designed to substitute Thr codon for the 4th codon of STII in accordance with the procedure of Step 4 to obtain a modified plasmid.

10 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid which contained a gene having Thr in place of the 4th amino acid of STII(SEQ ID NO: 14).

Met Lys Lys Thr Ile Ala Phe Leu (SEQ ID NO: 14)  
 5'-GG-TGT-TTT-ATG-AAA-AAG-ACA-ATC-GCA-TTT-CTT-C-3' (SEQ ID NO: 15)  
 15 3'-CC-ACA-AAA-TAC-TTT-TTC-TGT-TAG-CGT-AAA-GAA-G-5' (SEQ ID NO: 16)

The plasmid thus obtained was cleaved with XbaI and MluI, and then inserted at the XbaI/MluI section of vector pT14SSG obtained in step 4 to obtain vector pT14SSG-4T.

20

(Step 6) Construction of a vector containing a gene encoding modified STII /hG-CSF

25 Vector pT14SSG-4T obtained in Step 5 was subjected to PCR using the complementary primers of SEQ ID NOS: 18 and 19, which were designed to substitute Gln codon for the 22nd codon of STII in accordance with the procedure of Step 4 to obtain a modified plasmid.

30 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pT14SSG-4T22Q which contained a gene having Gln in place of the 22nd amino acid of STII(SEQ ID NO: 17).

ASN Ala Gln Ala Thr Pro Leu Gly (SEQ ID NO: 17)  
 35 5'-CA-AAT-GCC-CAA-GCG-ACA-CCC-CTG-GGC-3' (SEQ ID NO: 18)  
 3'-GT-TTA-CGG-GTT-CGC-TGT-GGG-GAC-CCG-5' (SEQ ID NO: 19)

(Step 7) Construction of a vector containing a modified STII SD and a gene encoding modified STII /hG-CSF

5           Vector pT14SSG-4T22Q obtained in Step 6 was subjected to PCR using the complementary primers of SEQ ID NOS: 20 and 21 in accordance with the procedure of Step 4 to obtain vector pT140SSG-4T22Q having the six nucleotide sequences between the STII SD sequence(GAGG) and the initiation codon of STII(modified STII SD of SEQ ID NO: 71).

10           Fig. 5 represents the above procedure for constructing vector pT140SSG-4T22Q.

*E. coli* BL21(DE3) was transformed with vector pT140SSG-4T22Q to obtain a transformant designated *E. coli* HM 10302.

15   Example 3: Construction of a vector containing a gene encoding modified hG-CSF

20           To prepare a modified hG-CSF gene, S1 oligomer(SEQ ID NO: 22) having *E. coli*-preferred codons and Ser in place of the 17th amino acid of hG-CSF and AS1 oligomer(SEQ ID NO: 23) were synthesized using DNA synthesizer(Model 380B, Applied Biosystem, USA).

25           0.5  $\mu$ l(50 pmole) quantities of the oligonucleotides were reacted at 95 °C for 15 min. and kept until 35 °C for 3 hours. The mixture was precipitated in ethanol and subjected to gel electrophoresis(SDS-PAGE) to obtain a cohesive ended double strand(ds) oligomer.

30           The plasmid pT14SS1SG obtained in step 3 of Example 2 was cleaved with ApaI and BstXI, and then ligated with the adhesive-ended ds oligomer, to obtain vector pT14SS1S17SEG. Vector pT14SS1S17SEG contained a gene encoding hG-CSF having *E. coli*-preferred codons at the amino terminus and Ser in place of the 1st and 17th amino acids of hG-CSF, respectively.

Fig. 6 illustrates the above procedure for constructing vector pT140SS1S17SEG.

35           *E. coli* BL21(DE3) was transformed with vector pT14SS1S17SEG to obtain a transformant designated *E. coli* HM 10311, which was deposited with Korean Culture Center of Microorganisms(KCCM) on March 24, 1999 under accession number KCCM-10154.

**Example 4:** Construction of vector containing a gene encoding *E. coli* OmpA signal peptide and modified hG-CSF

A vector containing a gene encoding Tac promoter and OmpA signal peptide(SEQ ID NO: 24) as well as a gene encoding modified hG-CSF was prepared as follows:

Met-Lys-Lys-Thr-Ala-Ile-Ala-Ile-Ala-Val-Ala-Leu-Ala-Gly-Phe-Ala-  
 Thr-Val-Ala-Gln-Ala- (SEQ ID NO: 24)  
 10 --GTT-GCG-CAA-GCT-TCT-CGA-- (SEQ ID NO: 25)  
 --CAA-CGC-GTT-CGA-AGA-GCT-- (SEQ ID NO: 26)  
 HindIII restriction site

Vector pT-CSF obtained in Example 1 was subjected to PCR using a  
 15 primer(SEQ ID NO: 27) designed to substitute Ser codon for the 1st codon of hG-CSF and another primer(SEQ ID NO: 28), to provide an EcoRI restriction site(5'-GAATTC-3') downstream from the termination codon thereof to obtain a DNA fragment containing a gene encoding modified hG-CSF .

The DNA fragment was cleaved with HindIII and EcoRI, and then  
 20 inserted at the HindIII/EcoRI section of vector pFlag.CTS(Eastman, USA) to obtain vector pTO1SG which contained a gene encoding *E. coli* OmpA signal peptide and modified hG-CSF(SEQ ID NO: 29).

Fig. 7 exhibits the above procedure for constructing vector pTO1SG.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector  
 25 pTO1SG to obtain a transformant designated *E. coli* HM 10409.

**Example 5:** Construction of a vector containing a gene encoding *E. coli* OmpA signal peptide and modified hG-CSF

30 The first codon of the modified hG-CSF gene of plasmid pTO1SG obtained in Example 4 was replaced by Thr in accordance with site-directed mutagenesis(Papworth, C. et al., *Strategies*, 9, 3(1996)), by conducting PCR of the plasmid pTO1SG obtained in Example 4 with a sense primer(SEQ ID NO: 30) designed to substitute Thr codon for the 1st codon of hG-CSF and a  
 35 complementary antisense primer(SEQ ID NO: 31).

*E. coli* XL-1 blue(Novagen, USA) was transformed with the modified

plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained plasmid pTOG which contained a gene having Thr in place of the first amino acid of hG-CSF.

5 *E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTOG to obtain a transformant designated *E. coli* HM 10401.

#### Example 6: Production of modified hG-CSFs

##### (a) Production of [Ser1, Ser17] hG-CSF

10 Vector pTO1SG obtained in Example 4 was subjected to PCR using a sense primer(SEQ ID NO: 32) designed to substitute Ser codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 33) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

15 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined and thus obtained was plasmid pTO1S17SG which contained a gene having Ser in place of the 1st and 17th amino acids of hG-CSF.

20 *E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTO1S17SG to obtain a transformant designated *E. coli* HM 10410, which was deposited with Korean Culture Center of Microorganisms(KCCM) on March 24, 1999 under accession number KCCM-10151.

##### (b) Production of [Ser17] hG-CSF

25 Vector pTOG obtained in Example 5 was subjected to PCR using a sense primer(SEQ ID NO: 32) designed to substitute Ser codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 33) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

30 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pTO17SG which contained a gene having Ser in place of the 17th amino acid of hG-CSF.

35 *E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTO17SG to obtain a transformant designated *E. coli* HM 10411, which was deposited with Korean Culture Center of Microorganisms(KCCM) on March 24,

1999 under accession number KCCM-10152.

(c) Production of [Thr17] hG-CSF

5 Vector pTOG obtained in Example 5 was subjected to PCR using a sense primer(SEQ ID NO: 34) designed to substitute Thr codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 35) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

10 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequences of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pTO17TG which contained a gene having Thr in place of the 17th amino acid of hG-CSF.

15 *E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTO17TG to obtain a transformant designated *E. coli* HM 10413.

(d) Production of [Ala17] hG-CSF

20 Vector pTOG obtained in Example 5 was subjected to PCR using a sense primer(SEQ ID NO: 36) designed to substitute Ala codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 37) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

25 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of DNA recovered from transformed colonies was determined, and thus obtained was plasmid pTO17AG which contained a gene having Ala in place of the 17th amino acid of hG-CSF.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTO17AG to obtain a transformant designated *E. coli* HM 10414.

(e) Production of [Gly17] hG-CSF

30 Vector pTOG obtained in Example 5 was subjected to PCR using a sense primer(SEQ ID NO: 38) designed to substitute Gly codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 39) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

35 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies

was determined, and thus obtained was plasmid pTO17GG which contained a gene having Gly in place of the 17th amino acids of hG-CSF.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTO17GG to obtain a transformant designated *E. coli* HM 10415.

5

(f) Production of [Asp17] hG-CSF

Vector pTOG obtained in Example 5 was subjected to PCR using a sense primer(SEQ ID NO: 40) designed to substitute Asp codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 41) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

*E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pTO17APG which contained a gene having Asp in place of the 17th amino acids of hG-CSF.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pTO17APG to obtain a transformant designated *E. coli* HM 10416.

Example 7: Construction of a vector containing a gene encoding *E. coli* Gene III signal peptide and modified hG-CSF

20

(a) Construction of a vector containing a gene encoding arabinose promoter and *E. coli* Gene III signal peptide

A vector containing a gene encoding arabinose promoter and *E. coli* Gene III signal peptide(SEQ ID NO: 42) as well as a gene encoding modified hG-CSG was prepared as follows:

Met-Lys-Lys-Leu-Leu-Phe-Ala-Ile-Pro-Leu-Val-Val-Pro-  
 30 Phe-Tyr-Ser-His-Ser- (SEQ ID NO: 42)  
 -TAT-AGC-CAT-AGC-ACC-ATG-GAG- (SEQ ID NO: 43)  
 -ATA-TCG-GTA-TCG-TGG-TAC-CTC- (SEQ ID NO: 44)  
 NcoI restriction site

35 Plasmid pBAD · gIIIa(Invitrogen, USA) containing a gene encoding arabinose promoter and Gene III signal peptide was cleaved with NcoI, and

single stranded DNAs were removed with Klenow DNA polymerase to obtain a blunt-ended double stranded DNA, which was then cleaved with BglII to obtain a vector fragment having both blunt end and a cohesive end.

5 Vector pT-CSF obtained in Example 1 was subjected to PCR using a sense primer(SEQ ID NO: 46) having a nucleotide sequence coding for the 2nd to the 9th amino acids of hG-CSF(SEQ ID NO: 45) and a complementary antisense primer(SEQ ID NO: 47) in accordance with the procedure of Step 4 of Example 2 to obtain a blunt-ended DNA fragment containing hG-CSF gene and a BamHI restriction site in the carboxy terminus. The fragment then was  
10 cleaved with BamHI to obtain hG-CSF gene fragment having both a blunt end and a cohesive end.

	Pro Leu Gly Pro Ala Ser Ser Leu	(SEQ ID NO 45)
5'	-C-CCC-CTG-GGC-CCT-GCC-AGC-TCC-CTG-3'	(SEQ ID NO 46)
15 3'	-G-GGG-GAC-CCG-GGA-CGG-TCG-AGG-GAC-5'	(SEQ ID NO 47)

The hG-CSF gene fragment as inserted into the vector obtained above to obtain vector pBADG which contained a gene encoding *E. coli* Gene III signal peptide and hG-CSF(SEQ ID NO: 48).

20 Fig. 8 describes the above procedure for constructing vector pBADG.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pBADG to obtain a transformant designated *E. coli* HM 10501.

#### (b) Production of [Met2, Val3] hG-CSF

25

Plasmid pBAD · gIIIA(Invitrogen, USA) was cleaved with NcoI and BglII to obtain a fragment having two cohesive ends.

Vector pT-CSF obtained in Example 1 was subjected to PCR using a sense primer(SEQ ID NO: 50) having a nucleotide sequence coding for the 1st to the 9th amino acids of [Met2, Val3] hG-CSF(SEQ ID NO: 49) and a complementary antisense primer(SEQ ID NO: 51) in accordance with the procedure of Step 4 of Example 2 to obtain a blunt-ended DNA fragment containing hG-CSF gene and a BamHI restriction site in the carboxy terminus, which was then was cleaved with NeoI and BamHI to obtain a hG-CSF gene  
35 fragment having two cohesive ends.



Thr Met Val Gly Pro Ala Ser Ser Leu (SEQ ID NO: 49)  
 5'-TAC-GCG-TCC-ATG-GTG-GGC-CCT-GCC-AGC-TCC-CTG-3' (SEQ ID NO: 50)  
 3'-ATG-CGC-AGG-TAC-CAC-CCG-GGA-CGG-TCG-AGG-GAC-5' (SEQ ID NO: 51)

5 NcoI restriction site

The hG-CSF gene fragment was inserted into the vector obtained above to obtain vector pBAD2M2VG contained a gene coding *E. coli* Gene III signal peptide, and Met and Val in place of the 2nd and 3rd amino acids of hG-CSF(SEQ ID NO: 52), respectively.

Fig. 9 shows the above procedure for constructing vector pBAD2M3VG.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pBAD2M3VG to obtain a transformant designated *E. coli* HM 10510, which was deposited with Korean Culture Center of Microorganisms(KCCM) on March 24, 1999 under accession number of KCCM-10153.

#### (c) Production of [Ser17] hG-CSF

20 Vector pBADG obtained in (a) was subjected to PCR using a sense primer(SEQ ID NO: 32) designed to substitute Ser codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 33) in accordance with the procedure of Step 4 of Example 2 to obtain a modified plasmid.

25 *E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pBAD17SG which contained a gene having Ser in place of the 17th amino acid of hG-CSF.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pBAD17SG to obtain a transformant designated *E. coli* HM 10511.

30

#### (d) Production of [Met2, Val3, Ser17] hG-CSF

35 Vector pBAD2M3VG obtained in (b) was subjected to PCR using a sense primer(SEQ ID NO: 32) designed to substitute Ser codon for the 17th codon of hG-CSF and a complementary antisense primer(SEQ ID NO: 33) in accordance with the procedure of Step 4 of Example 2 to obtain a modified

plasmid.

*E. coli* XL-1 blue(Novagen, USA) was transformed with the modified plasmid. The base sequence of the DNA recovered from transformed colonies was determined, and thus obtained was plasmid pBAD2M3V17SG which  
5 contained a gene having Met, Val and Ser in place of the 2nd, 3rd and 17th amino acids of hG-CSF, respectively.

*E. coli* BL21(DE3)(Stratagene, USA) was transformed with vector pBAD2M3V17SG to obtain a transformant designated *E. coli* HM 10512.

#### 10 Example 8: Production of hG-CSF

Transformants prepared in Examples 2 to 7 were cultured in LB medium(1% bacto-tryptone, 0.5% bacto-yeast extract and 1% NaCl) and then incubated in the presence of an expression inducer(IPTG) for 3 hours or  
15 cultured in the absence of IPTG more than 15 hours. Each of the cultures was centrifuged at 6,000 rpm for 20 min. to precipitate bacterial cells, and the precipitate was suspended in a 1/10 volume of isotonic solution(20 % sucrose, 10 mM Tris-Cl buffer solution containing 1 mM EDTA, pH 7.0). The suspension was allowed to stand at room temperature for 30 min, and then  
20 centrifuged at 7,000 rpm for 10 min. to collect bacterial cells. The cells were resuspended in D.W. at 4 °C and centrifuged at 7,000 rpm for 10 min. to obtain a supernatant as a periplasmic solution. The hG-CSF level in the periplasmic solution was assayed in accordance with ELISA method(Kato, K. et al., J. Immunol., 116, 1554(1976)) using an antibody against hG-CSF(Aland, USA),  
25 which was calculated as the amount of hG-CSF produced per 1 ℓ of culture. The results are shown in Table I.

Table 1

Transformant	Example	Expression Vector	hG-CSF Level in periplasm(mg/ℓ )
HM 10301	2(Step 4)	pT14SSG	65
HM 10302	2(Step 7)	pT140SSG-4T22Q	277
HM 10310	2(Step 3)	pT14SS1SG	92
HM 10311	3	pT14SS1S17SEG	1,512
HM 10401	5	pTOG	85
HM 10409	4	pTO1SG	105
HM 10410	6(a)	pTO1S17SG	1,477
HM 10411	6(b)	pTO17SG	1,550
HM 10413	6(c)	pTO17TG	1,373
HM 10414	6(d)	pTO17AG	1,486
HM 10415	6(e)	pTO17GG	1,480
HM 10416	6(f)	pTO17APG	67
HM 10501	7(a)	pBADG	54
HM 10510	7(b)	pBAD2M3VG	69
HM 10511	7(c)	pBAD17SG	937
HM 10512	7(d)	pBAD2M3V17SG	983

#### Example 9: Purification of hG-CSF

5

Transformant *E. coli* HM 10411 prepared in Example 6(b) was cultured in LB medium and the culture was centrifuged for 6,000 rpm for 20 min. to harvest cells. The periplasmic solution was prepared from the cells by repeating the procedure of Example 8.

10

The periplasmic solution was adjusted to pH 5.0 to 5.5, adsorbed on a CM-Sepharose(Pharmacia Inc., Sweden) column pre-equilibrated to pH 5.3, and then, the column was washed with 25 mM NaCl. hG-CSF was eluted by sequentially adding to the column buffer solutions containing 50mM, 100mM and 200mM NaCl, and fractions containing hG-SCF were collected and

15

combined. The combined fractions were subjected to Phenyl Sepharose(Pharmacia Inc., Sweden) column chromatography to obtain [Ser17] hG-CSF having a purity of 99%.

Further, the above procedure was repeated using each of the transformants *E. coli* HM 10311, HM 10409, HM 10411, HM 10413, HM 10414, HM 10415, HM 10510 and HM 10512 prepared in Examples 3, 4, 6(b), 6(c), 6(d), 6(e), 7(b) and 7(d), respectively.

5 Each of the purified hG-CSF fraction was subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis(SDS-PAGE) to determine the purity and approximate concentration of the hG-CSF, and then subjected to ELISA to determine the exact hG-CSF concentration in the periplasmic solution. Met-hG-CSF(Kirin amgen) was used as a control.

10 Fig. 10a reproduces the SDS-PAGE result, wherein lane 1 shows Met-G-CSF, lane 2, the periplasmic solution of the transformant *E. coli* HM 10411, and lane 3, the purified [Ser17] hG-CSF. As can be seen from Fig. 10b, the molecular weight of [Ser17] hG-CSF is the same as that of wild-type hG-CSF and the periplasmic solution of the transformant *E. coli* HM 10411 contains a  
15 high level of [Ser17] hG-CSF.

Further, the N-terminal amino acid sequences of hG-CSFs were determined and the nucleotide sequences coding for the 1st to 32nd amino acids produced using the transformants HM 10311, HM 10409, HM 10411, HM 10413, HM 10414, HM 10415, HM 10510 and HM 10512 shown in SEQ ID  
20 NOS: 56, 58, 60, 62, 64, 66, 68 and 70, respectively. The result shows that the modified hG-CSF produced according to the present invention is not methionylated at N-terminus.

A nitrocellulose filter (Bio-Rad Lab., USA) was wetted with a buffer solution for blotting(170 mM glycine, 25mM Tris · HCl(pH 8), 20% methanol)  
25 and the proteins separated on the gel were western blotted onto a nitrocellulose filter(Bio-Rad Lab., USA.) for 3 hours. The filter was kept in 1% Casein for 1 hour and was washed three times with PBS containing 0.05% Tween 20. The filter was put in a goat anti-G-CSF antibody(R&D System, AB-214-NA, USA) solution diluted with PBS and reacted at room temperature for 2 hours. After  
30 reaction, the filter was washed 3 times with a PBST solution to remove unreacted antibody. Horseradish peroxidase-conjugated rabbit anti-goat IgG(Bio-Rad Lab., USA) diluted with PBS was added thereto and reacted at room temperature for 2 hour . The filter was washed with PBST, and a peroxidase substance kit(Bio-Rad Lab.; USA) solution was added thereto to  
35 develop a color reaction. The results from the above western blotting are shown in Fig. 10b, wherein lane 1 represents a positive control, Met-G-CSF,

and lane 2, purified [Ser17] hG-CSF. As can be seen from Fig. 10b, the molecular weight of [Ser17] hG-CSF equals that of wild-type hG-CSF.

Example 10: Cellular Activity of hG-CSF and Modified hG-CSF

5

Cell line HL-60(ATCC CCL-240 derived from the bone marrow of a promyelocytic leukemia patient/a white 36-year-old woman) was cultured in RPMI 1640 media containing 10% fetal bovine serum and adjusted to  $2.2 \times 10^5$  cells/ml, followed by adding thereto DMSO(dimethylsulfoxide, culture grade/SIGMA) to a concentration of 1.25%(v/v). 90  $\mu\text{l}$  of the resulting solution was added to a 96 well plate(Corning/low evaporation 96 well plate) in an amount of  $2 \times 10^4$  cells/well and incubated at  $37^\circ\text{C}$  under 5%  $\text{CO}_2$  for 48 hours.

Each of the modified [Ala17] hG-CSF, [Gly 17] hG-CSF, [Ser17] hG-CSF, and [Thr 17] hG-CSF was diluted in RPMI 1640 media to a concentration of 500 ng/ml and then serially diluted 10 times by 2-fold with RPMI 1640 media.

The resulting solution was added to wells at 10  $\mu\text{l}$  per well and incubated at  $37^\circ\text{C}$  for 48 hours. As a positive control, a commercially available hG-CSF(Jeil Pharmaceutical.).

The level of cell line increased was determined using a commercially available CellTiter96<sup>TM</sup>(Cat # G4100, Promega) based on the measured optical density at 670 nm.

As can be seen from Fig. 11, the cellular activities of the modified hG-CSFs are the same as, or higher than of that the positive control, wild-type hG-CSF.

While the embodiments of the subject invention have been described and illustrated, it is obvious that various changes and modifications can be made therein without departing from the spirit of the present invention which should be limited only by the scope of the appended claims.

30